World Health Organization Regional Office for Africa, (WHO/AFRO), Brazzaville, Congo.
Centers for Disease Control and Prevention, Atlanta, GA, USA.
Vaccine. 2018 Nov 12;36(47):7119-7123. doi: 10.1016/j.vaccine.2018.06.026. Epub 2018 Jun 18.
By the end of 2017, 32 (68%) of 47 countries in the World Health Organization's African Region had introduced rotavirus vaccine into their national immunization programs, including 27 countries that received financial support from the Gavi, the Vaccine Alliance. Several early introducing African countries previously evaluated the impact, vaccine effectiveness, and/or cost effectiveness of their routine rotavirus vaccination programs and found that rotavirus vaccine was effective and resulted in substantial declines in hospitalizations due to rotavirus. This Special Issue of Vaccine provides additional rotavirus vaccine effectiveness and impact data from a broader range of African countries, describes the longer term impact and potential indirect benefits of rotavirus vaccination programs, describes trends in circulating genotypes in the pre- and post-vaccine introduction eras, and evaluates the cost-effectiveness of a rotavirus vaccination program in a post-introduction setting. As countries begin transitioning from Gavi support, the findings of these studies provide evidence of the impact and effectiveness of rotavirus vaccination programs under conditions of routine use.
截至 2017 年底，世卫组织非洲区域的 47 个国家中有 32 个（68%）将轮状病毒疫苗纳入本国免疫规划，其中包括 27 个得到疫苗联盟（Gavi）资助的国家。一些较早引入轮状病毒疫苗的非洲国家此前评估了常规轮状病毒疫苗接种规划的影响、疫苗效力和/或成本效益，发现轮状病毒疫苗有效，可大幅减少轮状病毒导致的住院病例。本期《疫苗》特刊提供了来自更多非洲国家的轮状病毒疫苗效力和影响数据，描述了轮状病毒疫苗接种规划的长期影响和潜在间接效益，描述了疫苗引入前后流行基因型的趋势，并评估了在疫苗引入后环境下轮状病毒疫苗接种规划的成本效益。随着各国开始逐步脱离疫苗联盟的支持，这些研究的结果为轮状病毒疫苗接种规划在常规使用条件下的影响和效果提供了证据。
